Phacilitate Leaders Forum

Phacilitate Leaders Europe Agenda 2018

Phacilitate Leaders Europe Agenda 2018

Loading
  1. Registration for Phacilitate Leaders Europe 2018 opens
  1. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  2. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  3. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  4. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  5. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  6. Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  1. Morning coffee
  1. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  2. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  3. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  4. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  5. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  6. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  7. Evaluating manufacturing capacity expansion in viral vectors and cell therapy for the long-term commercial feasibility of ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  1. A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

    Getting technical - Cell & Gene Therapy Europe
  2. A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

    Getting technical - Cell & Gene Therapy Europe
  3. A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

    Getting technical - Cell & Gene Therapy Europe
  4. A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

    Getting technical - Cell & Gene Therapy Europe
  5. A deep dive into process control: how can we increase quality through a comprehensive process control strategy?

    Getting technical - Cell & Gene Therapy Europe
  1. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

    Investment for Advanced Therapies
  2. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

    Investment for Advanced Therapies
  3. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part One

    Investment for Advanced Therapies
  4. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

    Investment for Advanced Therapies
  5. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

    Investment for Advanced Therapies
  6. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

    Investment for Advanced Therapies
  7. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

    Investment for Advanced Therapies
  8. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success

    Investment for Advanced Therapies
  1. Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

    Shared workshops
  2. Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

    Shared workshops
  3. Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

    Shared workshops
  4. Collaboration strategies: constructing a successful partnership with European clinical centres of excellence

    Shared workshops
  1. Buffet lunch and lunch workshop
  1. Optimising vector production platforms to meet future ATMP industry success

    Getting technical - Cell & Gene Therapy Europe
  2. Optimising vector production platforms to meet future ATMP industry success

    Getting technical - Cell & Gene Therapy Europe
  3. Optimising vector production platforms to meet future ATMP industry success

    Getting technical - Cell & Gene Therapy Europe
  4. Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

    Getting technical - Cell & Gene Therapy Europe
  5. Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

    Getting technical - Cell & Gene Therapy Europe
  6. Optimising vector production platforms to meet future ATMP industry success: viral and non-viral vectors under the microscope

    Getting technical - Cell & Gene Therapy Europe
  7. Optimising vector production platforms to meet future ATMP industry success

    Getting technical - Cell & Gene Therapy Europe
  1. Better together? Trends in combination partnering

    Immuno-Oncology Frontiers Europe
  2. Better together? Trends in combination partnering

    Immuno-Oncology Frontiers Europe
  3. Better together? Trends in combination partnering

    Immuno-Oncology Frontiers Europe
  4. Better together? Trends in combination partnering

    Immuno-Oncology Frontiers Europe
  5. Better together? Trends in combination partnering

    Immuno-Oncology Frontiers Europe
  1. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

    Investment for Advanced Therapies
  2. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

    Investment for Advanced Therapies
  3. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

    Investment for Advanced Therapies
  4. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

    Investment for Advanced Therapies
  5. Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?

    Investment for Advanced Therapies
  6. Next-gen cellular immunotherapy: breaking the barriers to solid tumour success - Part Two

  7. Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?

    Investment for Advanced Therapies
  1. Afternoon break
  1. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  2. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  3. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  4. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  5. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  6. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  7. Achieving commercial scale part 2: Industrialising the academic process for the scalability of cell & gene therapies

    Manufacturing Scalability - Cell & Gene Therapy Europe
  1. Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

    Getting technical - Cell & Gene Therapy Europe
  2. Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

    Getting technical - Cell & Gene Therapy Europe
  3. Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

    Getting technical - Cell & Gene Therapy Europe
  4. Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

    Getting technical - Cell & Gene Therapy Europe
  5. Gene therapy in the clinic : overcoming the in vivo clinical hurdles to ensure safe delivery to the patient and life time success of the vector

    Getting technical - Cell & Gene Therapy Europe
  1. Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

    Shared workshops
  2. Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

    Shared workshops
  3. Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

    Shared workshops
  4. Feedback loop: how are ATMP companies implementing the new GMP guidelines in Europe

    Shared workshops
  1. Close of day 1 and networking drinks
  1. Registration opens
  1. Morning coffee
  1. Planning for a successful supply chain strategy to harness globalisation and commercialisation for ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  2. Planning for a successful supply chain strategy to harness globalisation and commercialisation for ATMPs

    Manufacturing Scalability - Cell & Gene Therapy Europe
  1. Accurately predicting patient response

    Immuno-Oncology Frontiers Europe
  2. Accurately predicting patient response

    Immuno-Oncology Frontiers Europe
  3. Accurately predicting patient response

    Immuno-Oncology Frontiers Europe
  4. Accurately predicting patient response

    Immuno-Oncology Frontiers Europe
  5. Accurately predicting patient response

    Immuno-Oncology Frontiers Europe
  1. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  2. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  3. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  4. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  5. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  6. Next generation stem cell therapies: revived excitement in regenerative medicine

    Investment for Advanced Therapies
  1. Buffet lunch
  1. Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

    Manufacturing Scalability - Cell & Gene Therapy Europe
  2. Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

    Manufacturing Scalability - Cell & Gene Therapy Europe
  3. Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

    Manufacturing Scalability - Cell & Gene Therapy Europe
  4. Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

    Manufacturing Scalability - Cell & Gene Therapy Europe
  5. Utilizing the cutting edge of automation to drive robust, cost-effective cell-based therapy manufacturing at commercial scale

    Manufacturing Scalability - Cell & Gene Therapy Europe
  1. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  2. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  3. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  4. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  5. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  6. Cancer vaccines: the next frontier in cancer treatments?

    Investment for Advanced Therapies
  1. Afternoon tea
  1. The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

    Manufacturing Scalability - Cell & Gene Therapy Europe
  2. The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

    Manufacturing Scalability - Cell & Gene Therapy Europe
  3. The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

    Manufacturing Scalability - Cell & Gene Therapy Europe
  4. The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

    Manufacturing Scalability - Cell & Gene Therapy Europe
  5. The road to regulatory harmonisation for ATMP raw and starting material qualification, validation & selection on a European and global level

    Manufacturing Scalability - Cell & Gene Therapy Europe
  1. Oncolytic viruses: what is on the horizon for this emerging immuno-oncology treatment?

    Investment for Advanced Therapies
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd